A high interleukin 1 receptor antagonist/IL-1β ratio occurs naturally in knee osteoarthritis

Journal of Rheumatology

Volumn 35, Issue 8, 2008, Pages 1650-1654

  Richette, Pascal ^a,b,d   François, Mathias ^b   Vicaut, Eric ^a   Fitting, Catherine ^c   Bardin, Thomas ^a   Corvol, Maïté ^b   Savouret, Jean François ^b   Rannou, François ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c INSTITUT PASTEUR   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Interleukin 1; Interleukin 1 receptor antagonist; Osteoarthritis; Pain; Synovial fluid

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA;

ADULT; AGED; ARTICLE; CYTOKINE PRODUCTION; DISABILITY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KNEE OSTEOARTHRITIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; VISUAL ANALOG SCALE;

ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; SYNOVIAL FLUID;

EID: 49049087511     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jacques C, Gosset M, Berenbaum F, Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm 2006;74:371-403.
2. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002;13:323-40.
3. Palmer G, Mezin F, Juge-Aubry CE, Plater-Zyberk C, Gabay C, Guerne PA. Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann Rheum Dis 2004;63:43-9.
4. Palmer G, Guerne PA, Mezin F, et al. Production of interleukin-1 receptor antagonist by human articular chondrocytes. Arthritis Res 2002;4:226-31.
5. Henrotin YE, Zheng SX, Labasse AH, Deby GP, Crielaard JM, Reginster JY. Modulation of human chondrocyte metabolism by recombinant human interferon. Osteoarthritis Cartilage 2000;8:474-82.
6. Meier CA, Chicheportiche R, Juge-Aubry CE, Dreyer MG, Dayer JM. Regulation of the interleukin-1 receptor antagonist in THP-1 cells by ligands of the peroxisome proliferator-activated receptor gamma. Cytokine 2002;18:320-8.
7. Francois M, Richette P, Tsagris L, et al. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. Arthritis Rheum 2006;54:1233-45.
8. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990;85:1694-7.
9. Fernandes J, Tardif G, Martel-Pelletier J, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999;154:1159-69.
10. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002;9:12-20.
11. Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin I receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005;32:1317-23.
12. Chevalier X, Goupille P, Beaulieu A, et al. Results from a double blind, placebo-controlled, multicenter trial of a single intra-articular injection of anakinra (Kineret®) in patients with osteoarthritis of the knee [abstract]. Arthritis Rheum 2005;52 Suppl:S507.
13. Burger D, Dayer JM, Palmer G, Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis? Best Pract Res Clin Rheumatol 2006;20:879-96.
14. Pearle AD, Scanzello CR, George S, et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthritis Cartilage 2007;15:516-23.
15. Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. Arthritis Rheum 1993;36:781-9.
16. Corvol H, Fitting C, Chadelat K, et al. Distinct cytokine production by lung and blood neutrophils from children with cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2003;284:L997-1003.
17. Kobayashi M, Squires GR, Mousa A, et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005;52:128-35.
18. Goldring SR, Goldring MB. The role of cytokines in cartilage matrix degeneration in osteoarthritis. Clin Orthop Relat Res 2004:S27-36.
19. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001;44:1237-47.
20. Aigner T, Soder S, Gebhard PM, McAlinden A, Haag J. Mechanisms of disease: role of chondrocytes in the pathogenesis of osteoarthritis - structure, chaos and senescence. Nat Clin Pract Rheumatol 2007;3:391-9.
21. Goldring MB. Update on the biology of the chondrocyte and new approaches to treating cartilage diseases. Best Pract Res Clin Rheumatol 2006;20:1003-25.
22. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1 beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature 2001;410:471-5.
23. Felson DT. The sources of pain in knee osteoarthritis. Curr Opin Rheumatol 2005;17:624-8.
24. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997;24:365-71.
25. Brenner SS, Klotz U, Alscher DM, et al. Osteoarthritis of the knee - clinical assessments and inflammatory markers. Osteoarthritis Cartilage 2004;12:469-75.
26. Borderie D, Hilliquin P, Hernvann A, Kahan A, Menkes CJ, Ekindjian OG. Nitric oxide synthase is expressed in the lymphomononuclear cells of synovial fluid in patients with rheumatoid arthritis. J Rheumatol 1999;26:2083-8.
27. Brandt KD, Radin EL, Dieppe PA, van de Putte L. Yet more evidence that osteoarthritis is not a cartilage disease. Ann Rheum Dis 2006;65:1261-4.
28. Dieppe PA. Relationship between symptoms and structural change in osteoarthritis: what are the important targets for therapy? J Rheumatol 2005;32:1147-9.
29. Torres L, Dunlop DD, Peterfy C, et al. The relationship between specific tissue lesions and pain severity in persons with knee osteoarthritis. Osteoarthritis Cartilage 2006;14:1033-40.
30. Roux-Lombard P, Eberhardt K, Saxne T, Dayer JM, Wollheim FA. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology Oxford 2001;40:544-51.
31. Matsuzaki T, Nakajima A, Ishigami S, Tanno M, Yoshino S. Mirthful laughter differentially affects serum pro- and anti-inflammatory cytokine levels depending on the level of disease activity in patients with rheumatoid arthritis. Rheumatology Oxford 2006;45:182-6.
32. Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood 2005;105:2294-9.
33. Chikanza IC, Roux-Lombard P, Dayer JM, Panayi GS. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum 1995;38:642-8.